AtriCure (ATRC)
(Delayed Data from NSDQ)
$26.87 USD
+0.62 (2.36%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $26.88 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.87 USD
+0.62 (2.36%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $26.88 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -17.86% and 1.90%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm
by Zacks Equity Research
AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for January 22nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears
by Zacks Equity Research
Perrigo's (PRGO) shares rebound as the time to file an appeal against the Irish tax bill of $1.9 billion nears its deadline of Dec 28.
Perrigo Plunges on $1.9B Tax Bill From Irish Government
by Zacks Equity Research
Perrigo (PRGO), in a SEC filing, reports a $1.9 billion tax bill from Irish revenue department related to its subsidiary, Elan Pharma.
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 7.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
AtriCure (ATRC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 13.64% and 3.91%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for November 1st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
3 MedTech Stocks Poised to Trump Earnings in Q3
by Zacks Equity Research
Positive demographic trends, new product cycles, expansion into emerging markets and widespread consolidation are the key traits for the MedTech sector.